Modulation of Protein Stability in Cancer Therapy

Over the past two decades, there has been a tremendous increase in our understa- ing of ubiquitination and proteasome degradation. As the editors, we thank Springer Publishing for allowing us to organize this collection of reviews on the ubiquit- proteasome system, oncogenesis, and cancer therapy. We asked our colleagues, who are experts in the field, to provide an overview of their research and recent progress. Each chapter covers a broad range of topics that include defects in ubiquitination identified in specific tumors to new directions to treat cancer. In the Introduction, Rati Verma gives the background of our current understanding of the proteasome. A general overview of ubiquitin ligases and cancer is provided by Angelika Burger and Arun Seth. Patricia McChesney and Gary Kupfer discuss the role of the Fanconi anemia/BRCA1 pathways in breast cancer and potential targets for therapy. Defects in the tumor suppressor, von Hippel–Lindau E3 ligase, and the role of this protein complex are discussed by William Kim and William Kaelin. Kyung-bo Kim and colleagues describe the development of novel proteasome inhibitors to treat cancer patients. Progress in our understanding of deubiquitinating enzymes is summarized by Massimo Loda and his colleagues. Finally, Agustin Rodriguez-Gonzalez and Kathleen Sakamoto discuss an approach to recruit cancer-causing proteins to ub- uitin ligases through a chimeric molecule known as protacs.